Tomoya Hatayama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tomoya Hatayama has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Nobuyuki Hinata
Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
12 shared publications Keisuke Hieda
Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
10 shared publicationsAkihiro Goriki
Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
9 shared publications- Kohei Kobatake
Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
9 shared publications - Hiroyuki Kitano
Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
8 shared publications Keisuke Goto
Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
8 shared publications
Latest Publications
- Open Access
- 23 July 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (7) , e70579
External Validation of Prognostic Models for Nonmetastatic Clear Cell Renal Cell Carcinoma in a Japanese Cohort: Evaluation of Predictive Performance
Objectives: To characterize contemporary postoperative outcomes and risk stratification in a large Japanese real‐world cohort of patients with clinically nonmetastatic clear cell renal cell carcinoma (ccRCC), and to externally validate commonly used prognostic models. Methods: We retrospectively analyzed 1677 Japanese patients with clinically nonmetastatic ccRCC who underwent radical or partial nephrectomy between 2010 and 2025. Disease‐free survival (DFS) and overall survival (OS) were evaluated. The Leibovich score, SSIGN score, AUA risk groups, and GRANT score were externally validated. Model discrimination was assessed using Harrell's C‐index. Results: During a median follow‐up of 36 months, 160 patients (9.5%) experienced recurrence and 115 (6.9%) died, including 28 renal cancer‐specific deaths. The 3‐, 5‐, and 10‐year DFS rates were 91.2%, 87.6%, and 75.9%, respectively; corresponding OS rates were 95.0%, 91.1%, and 80.9%. Pathological T stage, WHO/ISUP grade, and lymphovascular invasion (LVI) were independently associated with DFS, whereas age, ASA physical status, and LVI were independently associated with OS. All four models significantly stratified DFS and OS. For DFS, the Leibovich score showed favorable discrimination, with a C‐index of 0.785 as a continuous score and 0.769 as a risk‐group model. In a post hoc exploratory analysis, adding LVI to the Leibovich score slightly increased the C‐index for DFS, but the improvement was not statistically significant. Conclusions: Established prognostic models consistently stratified recurrence risk in Japanese patients with clinically nonmetastatic ccRCC. The Leibovich score may serve as a useful reference for postoperative risk assessment, whereas the added value of LVI requires further validation.
- 23 July 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (7) , e70579
Open AccessExternal Validation of Prognostic Models for Nonmetastatic Clear Cell Renal Cell Carcinoma in a Japanese Cohort: Evaluation of Predictive Performance
Objectives: To characterize contemporary postoperative outcomes and risk stratification in a large Japanese real‐world cohort of patients with clinically nonmetastatic clear cell renal cell carcinoma (ccRCC), and to externally validate commonly used prognostic models. Methods: We retrospectively analyzed 1677 Japanese patients with clinically nonmetastatic ccRCC who underwent radical or partial nephrectomy between 2010 and 2025. Disease‐free survival (DFS) and overall survival (OS) were evaluated. The Leibovich score, SSIGN score, AUA risk groups, and GRANT score were externally validated. Model discrimination was assessed using Harrell's C‐index. Results: During a median follow‐up of 36 months, 160 patients (9.5%) experienced recurrence and 115 (6.9%) died, including 28 renal cancer‐specific deaths. The 3‐, 5‐, and 10‐year DFS rates were 91.2%, 87.6%, and 75.9%, respectively; corresponding OS rates were 95.0%, 91.1%, and 80.9%. Pathological T stage, WHO/ISUP grade, and lymphovascular invasion (LVI) were independently associated with DFS, whereas age, ASA physical status, and LVI were independently associated with OS. All four models significantly stratified DFS and OS. For DFS, the Leibovich score showed favorable discrimination, with a C‐index of 0.785 as a continuous score and 0.769 as a risk‐group model. In a post hoc exploratory analysis, adding LVI to the Leibovich score slightly increased the C‐index for DFS, but the improvement was not statistically significant. Conclusions: Established prognostic models consistently stratified recurrence risk in Japanese patients with clinically nonmetastatic ccRCC. The Leibovich score may serve as a useful reference for postoperative risk assessment, whereas the added value of LVI requires further validation.
- Open Access
- 5 June 2026
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (8) , 108-119
Nectin-4 drives aggressive tumor biology and poor prognosis in renal cell carcinoma
- 5 June 2026
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (8) , 108-119
Open AccessNectin-4 drives aggressive tumor biology and poor prognosis in renal cell carcinoma
- Open Access
Bone Marrow-Derived Mesenchymal Stem Cells Differentiate into Cancer-Associated Fibroblasts and Promote Tumor Growth in Renal Cell Carcinoma
Background: Tumor–stroma interactions play a critical role in renal cell carcinoma (RCC) progression. Cancer-associated fibroblasts (CAFs) are considered key components of the tumor microenvironment; however, their origin remains controversial. This study aimed to determine whether bone marrow-derived mesenchymal stem cells (MSCs) contribute to CAF-like stromal changes and RCC progression. Methods: An orthotopic xenograft mouse model was established using luciferase- and GFP-labeled Caki-1 cells. MSCs labeled with PKH26 were administered intravenously. Tumor growth was evaluated using an in vivo imaging system and tumor volume measurements. Immunohistochemical analyses were performed to assess MSC localization and α-smooth muscle actin (α-SMA) expression. In vitro proliferation and migration assays were conducted using direct and indirect co-culture systems. Results: The intravenous administration of MSCs significantly increased tumor growth and bioluminescence intensity in an orthotopic model. The tumor volumes were significantly larger in the MSC-treated versus control group. An immunofluorescence analysis demonstrated partial co-localization of PKH26-labeled MSCs with α-SMA-positive fibroblast-like cells, suggesting acquisition of CAF-like features. Direct co-culture with MSCs significantly enhanced RCC cell proliferation and migration in vitro, whereas culturing in conditioned medium alone did not produce similar effects. Conclusions: Exogenously administered bone marrow-derived MSCs may be recruited into RCC tissues and acquire CAF-like features through interactions with tumor cells. These findings suggest that stromal–tumor cell interactions within the tumor microenvironment may contribute to RCC progression and represent a potential therapeutic target.
Open AccessBone Marrow-Derived Mesenchymal Stem Cells Differentiate into Cancer-Associated Fibroblasts and Promote Tumor Growth in Renal Cell Carcinoma
Background: Tumor–stroma interactions play a critical role in renal cell carcinoma (RCC) progression. Cancer-associated fibroblasts (CAFs) are considered key components of the tumor microenvironment; however, their origin remains controversial. This study aimed to determine whether bone marrow-derived mesenchymal stem cells (MSCs) contribute to CAF-like stromal changes and RCC progression. Methods: An orthotopic xenograft mouse model was established using luciferase- and GFP-labeled Caki-1 cells. MSCs labeled with PKH26 were administered intravenously. Tumor growth was evaluated using an in vivo imaging system and tumor volume measurements. Immunohistochemical analyses were performed to assess MSC localization and α-smooth muscle actin (α-SMA) expression. In vitro proliferation and migration assays were conducted using direct and indirect co-culture systems. Results: The intravenous administration of MSCs significantly increased tumor growth and bioluminescence intensity in an orthotopic model. The tumor volumes were significantly larger in the MSC-treated versus control group. An immunofluorescence analysis demonstrated partial co-localization of PKH26-labeled MSCs with α-SMA-positive fibroblast-like cells, suggesting acquisition of CAF-like features. Direct co-culture with MSCs significantly enhanced RCC cell proliferation and migration in vitro, whereas culturing in conditioned medium alone did not produce similar effects. Conclusions: Exogenously administered bone marrow-derived MSCs may be recruited into RCC tissues and acquire CAF-like features through interactions with tumor cells. These findings suggest that stromal–tumor cell interactions within the tumor microenvironment may contribute to RCC progression and represent a potential therapeutic target.
- Open Access
- 30 April 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (5) , 102568
Comprehensive Analysis of Tumor Mutational Burden in Prostate Cancer: Multipublic Dataset Analysis
- 30 April 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (5) , 102568
Open AccessComprehensive Analysis of Tumor Mutational Burden in Prostate Cancer: Multipublic Dataset Analysis
- Open Access
- 26 January 2026
- Published by Wiley in The Prostate
- Vol. 86 (6) , 689-696
Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis
Background: In prostate cancer (PCa), smoking history is associated with more aggressive clinicopathological features, reduced efficacy of androgen deprivation therapy, and poorer overall survival (OS). However, its impact on survival outcomes in patients receiving taxane chemotherapy, poly ADP‐ribose polymerase inhibitor (PARPi), or immune checkpoint inhibitor (ICI) therapy for PCa remains unclear. We compared the genetic profiles of smokers and non‐smokers with PCa in several public databases to explore the potential influence of smoking on treatment outcomes. Methods: We retrospectively collected data on smoking history, tumor characteristics, genomic information, treatment history, and survival outcomes from three public databases to investigate the role of smoking in PCa. Patients were categorized into smokers and non‐smokers, and associations between smoking history and clinicopathological features, genetic profiles, and treatment outcomes were analyzed. Independent risk factors for OS were evaluated using multivariate Cox proportional hazard regression models. Results: Smokers exhibited significantly higher Gleason score, clinical stage, tumor mutational burden, fraction genome altered, and microsatellite instability scores than non‐smokers. The survival analysis revealed that smokers had significantly poorer OS than non‐smokers in the overall, hormone therapy, and PARPi therapy cohorts. In contrast, no significant difference in OS was observed between the taxane chemotherapy and ICI therapy cohorts. Furthermore, multivariate Cox proportional hazard regression analysis identified smoking history as an independent risk factor for OS in the overall, hormone therapy, and PARPi therapy cohorts. Oncoplot analysis showed a significantly higher frequency of TP53 mutations and PTEN copy number alterations in smokers than in non‐smokers. Conclusions: Smoking history was significantly associated with aggressive clinicopathological features and a poor prognosis in patients with PCa. Our findings suggest that smokers with PCa may receive greater benefit from the early administration of taxane chemotherapy in comparison to other treatment regimens.
- 26 January 2026
- Published by Wiley in The Prostate
- Vol. 86 (6) , 689-696
Open AccessGenomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis
Background: In prostate cancer (PCa), smoking history is associated with more aggressive clinicopathological features, reduced efficacy of androgen deprivation therapy, and poorer overall survival (OS). However, its impact on survival outcomes in patients receiving taxane chemotherapy, poly ADP‐ribose polymerase inhibitor (PARPi), or immune checkpoint inhibitor (ICI) therapy for PCa remains unclear. We compared the genetic profiles of smokers and non‐smokers with PCa in several public databases to explore the potential influence of smoking on treatment outcomes. Methods: We retrospectively collected data on smoking history, tumor characteristics, genomic information, treatment history, and survival outcomes from three public databases to investigate the role of smoking in PCa. Patients were categorized into smokers and non‐smokers, and associations between smoking history and clinicopathological features, genetic profiles, and treatment outcomes were analyzed. Independent risk factors for OS were evaluated using multivariate Cox proportional hazard regression models. Results: Smokers exhibited significantly higher Gleason score, clinical stage, tumor mutational burden, fraction genome altered, and microsatellite instability scores than non‐smokers. The survival analysis revealed that smokers had significantly poorer OS than non‐smokers in the overall, hormone therapy, and PARPi therapy cohorts. In contrast, no significant difference in OS was observed between the taxane chemotherapy and ICI therapy cohorts. Furthermore, multivariate Cox proportional hazard regression analysis identified smoking history as an independent risk factor for OS in the overall, hormone therapy, and PARPi therapy cohorts. Oncoplot analysis showed a significantly higher frequency of TP53 mutations and PTEN copy number alterations in smokers than in non‐smokers. Conclusions: Smoking history was significantly associated with aggressive clinicopathological features and a poor prognosis in patients with PCa. Our findings suggest that smokers with PCa may receive greater benefit from the early administration of taxane chemotherapy in comparison to other treatment regimens.
- Open Access
- 29 November 2025
- Published by Wiley in Cancer Science
- Vol. 117 (2) , 364-376
Crucial Contribution of BACH1 to Bladder Cancer Progression via Upregulating Epithelial‐Mesenchymal Transition Pathway
Bladder cancer (BC) is a prevalent urological malignancy, with muscle‐invasive subtypes exhibiting a particularly poor prognosis despite recent therapeutic advances. Established risk factors such as smoking contribute to carcinogenesis through the generation of reactive oxygen species, which trigger oxidative stress responses (OSRs). Broad‐complex‐Tramtrack‐Bric a brac and Cap'n' collar homology 1 (BACH1), a key transcription factor regulating OSRs, has been implicated in epithelial‐mesenchymal transition (EMT) and metastasis in several malignancies. This study aimed to clarify the role of BACH1 in BC progression and metastasis. Clinical analyses revealed that BACH1‐positive expression was correlated with aggressive tumor features, including advanced pathological stage, high tumor grade, and poor prognosis. In vitro experiments demonstrated that BACH1 knockdown suppressed, while overexpression enhanced, the invasive, migratory, and proliferative activities. RNA sequencing indicated significant enrichment of EMT‐related and cytokine‐driven immune pathways following BACH1 knockdown. Furthermore, in vivo mouse allograft experiments showed that Bach1 knockout cells exhibited reduced tumor growth and fewer lung metastases, accompanied by altered expression of EMT markers and modulation of cytokine‐driven immune signaling. Collectively, these findings suggest that BACH1 plays a crucial role in BC progression and metastasis, at least in part, through two complementary mechanisms, EMT activation and immune microenvironment modulation via cytokine signaling.
- 29 November 2025
- Published by Wiley in Cancer Science
- Vol. 117 (2) , 364-376
Open AccessCrucial Contribution of BACH1 to Bladder Cancer Progression via Upregulating Epithelial‐Mesenchymal Transition Pathway
Bladder cancer (BC) is a prevalent urological malignancy, with muscle‐invasive subtypes exhibiting a particularly poor prognosis despite recent therapeutic advances. Established risk factors such as smoking contribute to carcinogenesis through the generation of reactive oxygen species, which trigger oxidative stress responses (OSRs). Broad‐complex‐Tramtrack‐Bric a brac and Cap'n' collar homology 1 (BACH1), a key transcription factor regulating OSRs, has been implicated in epithelial‐mesenchymal transition (EMT) and metastasis in several malignancies. This study aimed to clarify the role of BACH1 in BC progression and metastasis. Clinical analyses revealed that BACH1‐positive expression was correlated with aggressive tumor features, including advanced pathological stage, high tumor grade, and poor prognosis. In vitro experiments demonstrated that BACH1 knockdown suppressed, while overexpression enhanced, the invasive, migratory, and proliferative activities. RNA sequencing indicated significant enrichment of EMT‐related and cytokine‐driven immune pathways following BACH1 knockdown. Furthermore, in vivo mouse allograft experiments showed that Bach1 knockout cells exhibited reduced tumor growth and fewer lung metastases, accompanied by altered expression of EMT markers and modulation of cytokine‐driven immune signaling. Collectively, these findings suggest that BACH1 plays a crucial role in BC progression and metastasis, at least in part, through two complementary mechanisms, EMT activation and immune microenvironment modulation via cytokine signaling.
- Open Access
- 14 September 2025
- Published by Wiley in International Journal of Urology
- Vol. 32 (12) , 1819-1826
Efficacy of Open‐Ended Urinary Catheters in Preventing Catheter‐Related Bladder Discomfort: A Randomized Controlled Trial
Objective: Catheter‐related bladder discomfort (CRBD) is a common postoperative complication following urological procedures, causing significant distress and reducing patient satisfaction. Although pharmacological interventions have been investigated, a more definitive approach is warranted. This study evaluated whether an open‐ended Foley catheter (OEFC) reduces the incidence and severity of CRBD compared with a conventional Foley catheter (FC). Materials: In this exploratory, parallel‐group, single‐blind, randomized controlled trial conducted at Hiroshima University Hospital, 100 patients undergoing transurethral resection of a bladder tumor or robot‐assisted surgery for renal, renal pelvic, or ureteral malignancies were randomized 1:1 to receive either an OEFC or a standard FC. The primary endpoint was the incidence of CRBD at 6 h postoperatively. Secondary endpoints included the incidence and severity of CRBD and urethral pain, and the frequency of pharmacological intervention at predefined postoperative time points. Results: Ninety‐four patients were included in the full analysis set (47 per group). At 6 h postoperatively, CRBD incidence was significantly lower in the OEFC group than in the FC group (42.6% vs. 68.1%; p = 0.012). The OEFC group consistently demonstrated reduced CRBD incidence and severity compared with the FC group during the first 6 h. Urethral pain scores and analgesic use were comparable between groups. Subgroup analyses indicated that the preventive effect of OEFC was particularly notable in non‐transurethral resection of bladder tumor patients. Conclusions: OEFC placement represents a broadly applicable and effective strategy to reduce CRBD following urological surgery. Catheter tip design appears to play a pivotal role in CRBD prevention.
- 14 September 2025
- Published by Wiley in International Journal of Urology
- Vol. 32 (12) , 1819-1826
Open AccessEfficacy of Open‐Ended Urinary Catheters in Preventing Catheter‐Related Bladder Discomfort: A Randomized Controlled Trial
Objective: Catheter‐related bladder discomfort (CRBD) is a common postoperative complication following urological procedures, causing significant distress and reducing patient satisfaction. Although pharmacological interventions have been investigated, a more definitive approach is warranted. This study evaluated whether an open‐ended Foley catheter (OEFC) reduces the incidence and severity of CRBD compared with a conventional Foley catheter (FC). Materials: In this exploratory, parallel‐group, single‐blind, randomized controlled trial conducted at Hiroshima University Hospital, 100 patients undergoing transurethral resection of a bladder tumor or robot‐assisted surgery for renal, renal pelvic, or ureteral malignancies were randomized 1:1 to receive either an OEFC or a standard FC. The primary endpoint was the incidence of CRBD at 6 h postoperatively. Secondary endpoints included the incidence and severity of CRBD and urethral pain, and the frequency of pharmacological intervention at predefined postoperative time points. Results: Ninety‐four patients were included in the full analysis set (47 per group). At 6 h postoperatively, CRBD incidence was significantly lower in the OEFC group than in the FC group (42.6% vs. 68.1%; p = 0.012). The OEFC group consistently demonstrated reduced CRBD incidence and severity compared with the FC group during the first 6 h. Urethral pain scores and analgesic use were comparable between groups. Subgroup analyses indicated that the preventive effect of OEFC was particularly notable in non‐transurethral resection of bladder tumor patients. Conclusions: OEFC placement represents a broadly applicable and effective strategy to reduce CRBD following urological surgery. Catheter tip design appears to play a pivotal role in CRBD prevention.
- Open Access
- 1 September 2025
- Published by Wiley in The Prostate
- Vol. 85 (16) , 1513-1521
Comprehensive Analysis of Fraction of Genome Altered in Prostate Cancer Treatment
Background: Genomic instability is a key feature of cancer and plays a central role in tumor progression. One emerging metric for genomic instability is the fraction of genome altered (FGA), which quantifies the proportion of the genome affected by copy number alterations. Previous studies in various solid tumors have shown that high FGA is associated with aggressive disease and adverse clinical outcomes. However, the clinical significance of FGA in prostate cancer (PC) remains unclear. In this study, we investigated the role of FGA as a potential biomarker of tumor aggressiveness and a poor prognosis in PC using several large‐scale public databases. Methods: We analyzed the processed data from previous large‐scale PC studies available through the cBioPortal database: MSK CHORD 2024 ( n = 3211), MSK 2021 ( n = 2069), MSK 2020 mCSPC ( n = 424), SU2C/PCF mCRPC ( n = 444), and AACR Project GENIE ( n = 5306). Associations between FGA and clinical parameters such as T stage, Gleason score (GS), tumor volume, metastatic burden, pathological subtype, and treatment history were evaluated. Kaplan–Meier survival analysis was used to assess the prognostic value of FGA. Results: High FGA was significantly associated with aggressive clinical features, including higher T stage, GS, metastatic burden, and neuroendocrine prostate cancer histology. FGA increased after most therapeutic interventions. Patients with high FGA had significantly poorer overall survival across nearly all treatment modalities. An oncoplot analysis revealed a higher frequency of somatic alterations in key driver genes, including AR, PTEN , and TP53 , in high‐FGA tumors. Conclusions: FGA was closely associated with tumor aggressiveness, therapy‐induced genomic instability, and a poor prognosis in PC. It may serve as a clinically relevant biomarker across diverse treatment contexts.
- 1 September 2025
- Published by Wiley in The Prostate
- Vol. 85 (16) , 1513-1521
Open AccessComprehensive Analysis of Fraction of Genome Altered in Prostate Cancer Treatment
Background: Genomic instability is a key feature of cancer and plays a central role in tumor progression. One emerging metric for genomic instability is the fraction of genome altered (FGA), which quantifies the proportion of the genome affected by copy number alterations. Previous studies in various solid tumors have shown that high FGA is associated with aggressive disease and adverse clinical outcomes. However, the clinical significance of FGA in prostate cancer (PC) remains unclear. In this study, we investigated the role of FGA as a potential biomarker of tumor aggressiveness and a poor prognosis in PC using several large‐scale public databases. Methods: We analyzed the processed data from previous large‐scale PC studies available through the cBioPortal database: MSK CHORD 2024 ( n = 3211), MSK 2021 ( n = 2069), MSK 2020 mCSPC ( n = 424), SU2C/PCF mCRPC ( n = 444), and AACR Project GENIE ( n = 5306). Associations between FGA and clinical parameters such as T stage, Gleason score (GS), tumor volume, metastatic burden, pathological subtype, and treatment history were evaluated. Kaplan–Meier survival analysis was used to assess the prognostic value of FGA. Results: High FGA was significantly associated with aggressive clinical features, including higher T stage, GS, metastatic burden, and neuroendocrine prostate cancer histology. FGA increased after most therapeutic interventions. Patients with high FGA had significantly poorer overall survival across nearly all treatment modalities. An oncoplot analysis revealed a higher frequency of somatic alterations in key driver genes, including AR, PTEN , and TP53 , in high‐FGA tumors. Conclusions: FGA was closely associated with tumor aggressiveness, therapy‐induced genomic instability, and a poor prognosis in PC. It may serve as a clinically relevant biomarker across diverse treatment contexts.
- Open Access
- 18 July 2025
- Published by Wiley in International Journal of Urology
- Vol. 32 (11) , 1576-1586
Association Between Preoperative Penile Circumference and Urinary Function After Robot‐Assisted Radical Prostatectomy
Objectives: This study investigated whether preoperative penile length, penile circumference, and testis size are associated with urinary function and sexual function after robot‐assisted radical prostatectomy (RARP). Methods: We retrospectively analyzed 197 Japanese patients who underwent RARP. Patients were categorized based on the median preoperative penile length, penile circumference, and testis size. Urinary function and sexual function were assessed based on the daily pad usage and the results of the Expanded Prostate Cancer Index Composite (EPIC), International Prostate Symptom Score (IPSS), and International Index of Erectile Function‐5 (IIEF‐5) questionnaires preoperatively and 1, 3, 6, and 12 months postoperatively. Results: Preoperative penile circumference was significantly associated with postoperative urinary outcomes. The thick penis group (larger than the median preoperative penile circumference) used fewer daily pads and had better urinary function scores (EPIC and IPSS) compared to the thin penis group (median or smaller preoperative penile circumference) postoperatively. In contrast, preoperative penile length exhibited no significant relationship with postoperative urinary function. Postoperative sexual function scores (EPIC and IIEF‐5) showed trends that favored the long (longer than the median preoperative penile length) and thick penis groups than the short (median or shorter preoperative penile length) and thin penis groups, but significant differences were limited to specific time points. Preoperative testis size exhibited no significant relationship with urinary and sexual outcomes. Conclusions: The preoperative penile circumference was associated with urinary function after RARP, highlighting its potential as a practical clinical marker. However, the association between preoperative penile size and sexual function was minimal.
- 18 July 2025
- Published by Wiley in International Journal of Urology
- Vol. 32 (11) , 1576-1586
Open AccessAssociation Between Preoperative Penile Circumference and Urinary Function After Robot‐Assisted Radical Prostatectomy
Objectives: This study investigated whether preoperative penile length, penile circumference, and testis size are associated with urinary function and sexual function after robot‐assisted radical prostatectomy (RARP). Methods: We retrospectively analyzed 197 Japanese patients who underwent RARP. Patients were categorized based on the median preoperative penile length, penile circumference, and testis size. Urinary function and sexual function were assessed based on the daily pad usage and the results of the Expanded Prostate Cancer Index Composite (EPIC), International Prostate Symptom Score (IPSS), and International Index of Erectile Function‐5 (IIEF‐5) questionnaires preoperatively and 1, 3, 6, and 12 months postoperatively. Results: Preoperative penile circumference was significantly associated with postoperative urinary outcomes. The thick penis group (larger than the median preoperative penile circumference) used fewer daily pads and had better urinary function scores (EPIC and IPSS) compared to the thin penis group (median or smaller preoperative penile circumference) postoperatively. In contrast, preoperative penile length exhibited no significant relationship with postoperative urinary function. Postoperative sexual function scores (EPIC and IIEF‐5) showed trends that favored the long (longer than the median preoperative penile length) and thick penis groups than the short (median or shorter preoperative penile length) and thin penis groups, but significant differences were limited to specific time points. Preoperative testis size exhibited no significant relationship with urinary and sexual outcomes. Conclusions: The preoperative penile circumference was associated with urinary function after RARP, highlighting its potential as a practical clinical marker. However, the association between preoperative penile size and sexual function was minimal.
- Open Access
- 20 February 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-8
The advanced lung cancer inflammation index as a useful prognostic indicator for patients who underwent radical nephroureterectomy for upper tract urothelial carcinoma
Purpose: We aimed to evaluate the ability of the advanced lung cancer inflammation index (ALI) to predict the prognosis of patients who underwent radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). We also aimed to compare the ALI with other inflammatory or nutritional indices as prognostic indicators. Methods: We retrospectively evaluated patients who underwent RNU for UTUC at multiple centers between January 2010 and April 2024. We calculated the ALI before RNU and divided the patients into the low ALI and high ALI groups. We used 1:1 propensity score matching (PSM) to adjust the clinicopathological differences between two groups. We compared the overall survival (OS) and recurrence-free survival (RFS) of the low and high ALI groups using the Kaplan-Meier method. Furthermore, we assessed the ALI as a predictor of OS and RFS using a multivariate Cox proportional hazards regression analysis. Results: Of 488 patients (48.3% low ALI group), 160 patients from each group were matched. The Kaplan-Meier analysis revealed that the OS ( p = 0.009) and RFS ( p = 0.006) of the low ALI group were significantly shorter than those of the high ALI group. According to a multivariate analysis that included clinicopathological prognostic indicators, a low ALI was an independent predictor of poor OS ( p = 0.014) and RFS ( p = 0.038). Furthermore, according to the multivariate analysis including other inflammatory or nutritional indices, the ALI was an independent predictor of poor OS ( p = 0.024) and RFS ( p = 0.044). Conclusions: The ALI was a significantly useful prognostic predictors of patients with UTUC who underwent RNU.
- 20 February 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-8
Open AccessThe advanced lung cancer inflammation index as a useful prognostic indicator for patients who underwent radical nephroureterectomy for upper tract urothelial carcinoma
Purpose: We aimed to evaluate the ability of the advanced lung cancer inflammation index (ALI) to predict the prognosis of patients who underwent radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). We also aimed to compare the ALI with other inflammatory or nutritional indices as prognostic indicators. Methods: We retrospectively evaluated patients who underwent RNU for UTUC at multiple centers between January 2010 and April 2024. We calculated the ALI before RNU and divided the patients into the low ALI and high ALI groups. We used 1:1 propensity score matching (PSM) to adjust the clinicopathological differences between two groups. We compared the overall survival (OS) and recurrence-free survival (RFS) of the low and high ALI groups using the Kaplan-Meier method. Furthermore, we assessed the ALI as a predictor of OS and RFS using a multivariate Cox proportional hazards regression analysis. Results: Of 488 patients (48.3% low ALI group), 160 patients from each group were matched. The Kaplan-Meier analysis revealed that the OS ( p = 0.009) and RFS ( p = 0.006) of the low ALI group were significantly shorter than those of the high ALI group. According to a multivariate analysis that included clinicopathological prognostic indicators, a low ALI was an independent predictor of poor OS ( p = 0.014) and RFS ( p = 0.038). Furthermore, according to the multivariate analysis including other inflammatory or nutritional indices, the ALI was an independent predictor of poor OS ( p = 0.024) and RFS ( p = 0.044). Conclusions: The ALI was a significantly useful prognostic predictors of patients with UTUC who underwent RNU.